-
Nullscript: A Practical HDAC Inhibitor Workflow
2026-09-18
Nullscript is a histone deacetylase inhibitor designed for experiments that separate HDAC-dependent chromatin effects from transcriptional reporter activation. Its reporter-inactive profile and preclinical cardiac ischemia/reperfusion signal make it useful for orthogonal assay design, mechanism testing, and translational model development.
-
Ion-Enhanced CPP Delivery of Nucleic Acids
2026-09-18
The reference study shows that biocompatible ions can reshape cell-penetrating peptide–nucleic acid nanoparticles and improve productive intracellular delivery, with multivalent ions exerting particularly strong effects. Its central contribution is to separate nanoparticle internalization from functional delivery, indicating that ion supplementation primarily benefits endosomal escape and downstream nucleic acid activity.
-
Tubastatin A: From HDAC6 Biology to Translation
2026-09-17
Tubastatin A is a highly selective HDAC6 inhibitor that connects acetylation biology with cytoskeletal regulation, inflammatory signaling, and programmed cell death. New porcine cardiac-arrest data extend its translational relevance beyond conventional cancer and neurobiology models, while also highlighting the evidence requirements for moving from mechanistic promise to robust preclinical strategy.
-
EZ Cap™ Human PTEN mRNA (ψUTP): Assay Design
2026-09-17
Discover how EZ Cap™ Human PTEN mRNA (ψUTP) can function as a mechanistically controlled PTEN-restoration tool in cancer research. This guide connects Cap 1 and pseudouridine design with delivery controls, PI3K/Akt pathway readouts, and resistance-model assay decisions.
-
GW 6471: PPARα Antagonist Workflow
2026-09-16
GW 6471 enables controlled interrogation of PPARα-dependent transcription in metabolic, lipid, and toxicology models. This workflow-oriented guide combines pharmacological inhibition with transcript, biochemical, and phenotype-level readouts to distinguish pathway association from causal involvement.
-
Aconitase Activity Colorimetric Assay Kit Guide
2026-09-16
The Aconitase Activity Colorimetric Assay Kit K2226 provides a rapid, 450 nm colorimetric readout of functional aconitase activity. It connects TCA cycle enzyme assay data with oxidative damage measurement while complementing, rather than replacing, broader immunometabolic analyses.
-
WST-8 Glucose Uptake Assay Kit: Practical Guide
2026-09-15
This scenario-based guide explains how the WST-8 Glucose Uptake Assay Kit, SKU K2303, supports quantitative, non-radioactive glucose uptake measurement across metabolic, cancer, and diabetes research. It covers assay principles, experimental controls, protocol parameters, interpretation, and practical vendor-selection criteria.
-
Fucoidan Workflows for Breast Cancer Research
2026-09-15
Build a practical Fucoidan workflow that connects MCF-7 viability, migration, colony formation, and caveolin-1 analysis with orthogonal cancer biology readouts. The approach also shows how to compare a marine sulfated polysaccharide with tamoxifen while controlling solubility, vehicle, and assay-specific artifacts.
-
SERF as a Modifier of Amyloid Formation
2026-09-14
The dissertation “SERF is a modifier of amyloid formation” examines how SERF/MOAG-4 influences amyloid biology through complementary yeast, molecular, and protein-biochemical approaches. Its main contribution is to position SERF as a regulatory modifier of amyloid formation and to connect genetic perturbation with biochemical analysis of soluble and insoluble protein states.
-
WST-8 Glucose Uptake Assay: Readout and Design
2026-09-14
The WST-8 Glucose Uptake Assay Kit provides a non-radioactive, colorimetric route to quantify cellular glucose uptake. This article explains how to interpret the redox-linked signal, design controls for ion-modulated transfection studies, and distinguish transport from downstream metabolic effects.
-
Chenodeoxycholic Acid: From FXR Ligand to Assay
2026-09-13
Chenodeoxycholic Acid is more than a bile acid metabolism reagent: it is a mechanistic probe for connecting FXR transcriptional activity with inflammatory and injury phenotypes. This guide translates recent FXR–KLF11 findings into practical assay design, controls, and interpretation strategies.
-
GLI2–PRDX1 Ferroptosis Resistance in Bladder Cancer
2026-09-12
The reference study identifies a GLI2–PRDX1 transcriptional axis that suppresses ferroptosis and promotes malignant behavior in bladder cancer cells. Its combination of public-data analysis, RNA sequencing, chromatin immunoprecipitation, genetic perturbation, and drug-sensitization experiments provides a mechanistic framework for studying GLI2-dependent cisplatin resistance.
-
Metoprolol Tartrate in β1 Cardiovascular Research
2026-09-11
Metoprolol Tartrate is a selective β1-adrenergic blocking agent for cardiovascular research involving heart rate, contractility, hypertension, angina, and arrhythmia biology. A recent mouse and human hematopoietic cell transplant study found that β1-selective metoprolol did not reproduce the engraftment impairment associated with nonselective β-blockade.
-
Metoprolol Tartrate for β1-Selective Research
2026-09-11
Metoprolol Tartrate enables controlled β1-adrenergic receptor inhibition in cardiomyocyte, vascular, and transplantation-related assays. Its selectivity provides a practical contrast with nonselective β-blockade, helping researchers separate cardiac receptor effects from β2/β3-dependent regenerative pathways.
-
Neomycin Sulfate for RNA/DNA Assays
2026-09-10
Neomycin sulfate is an aminoglycoside antibiotic that serves as a mechanistic probe for ribozyme catalysis, HIV-1 Tat–TAR recognition, DNA triplexes, and ryanodine receptor currents. This guide translates its binding and channel effects into practical assay workflows while showing how to avoid confounding antibiotic, ionic-strength, and storage variables.